경동제약

011040KOSDAQ

68.6 / 100

Reference Date: 2026-09-08

Financial Score23.0 / 40

News Sentiment20.6 / 25

Momentum13.0 / 20

Disclosure12.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly up 2.4% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Gyeongdong Pharmaceutical, established in 1976, is a company specializing in the manufacturing and sales of pharmaceuticals. Its business segments include pharmaceuticals (accounting for ~95% of sales), leasing, and others. Key products include DuoLoban tablets and Alpotin soft capsules, targeting rising demand due to aging populations and Western dietary habits. The company is expanding exports and developing new products, including OTC drugs and health supplements.

Number of Employees

363people

Average Salary

56.0M KRW

Score Calculation Basis

Detailed Financial Score

PER

16.33Industry Average 15.003.0Point

Higher than industry avg (caution)

PBR

0.69Industry Average 1.205.5Point

Lower than industry avg (good)

ROE

3.76Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

10.24Industry Average 100.008.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

2.5 / 3

Avg ▲10.2% (2-year basis)

Operating Profit Growth Rate

3.0 / 3

Avg ▲151.4% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -0.8% (improving, 3yr)

Detailed News Sentiment

4 totalPositive 4Neutral 0Negative 0Average Sentiment Score 82.5

Positive
주 1회 세마글루타이드, 월 1회 투여형 개발?경동제약·아울바이오 1....
경동제약과 아울바이오의 세마글루타이드 장기지속형 주사제 AUL009 임상 1상 IND 제출로 긍정적인 시장 반응 예상.
Positive
펌프 명가 한일전기, 중남미서 수출길 개척 나선다
한일전기의 중남미 진출로 경동제약과 관련된 간접적인 성장 동력이 마련되어 긍정적 영향 기대.
Positive
경동제약, 창사 첫 반기 매출 1000억원 돌파
경동제약의 반기 매출이 창사 이래 처음으로 1000억원을 돌파하며, 지속적인 비용 절감과 R&D 투자로 인한 성장이 확인되었다.

Detailed Momentum

52-week position3.0Point

52w lower range (30%)

Current 5,160Won52-week high 6,16052-week low 4,720

1-month return4.0Point

1m +2.38% (slight rise)

Volume trend6.0Point

Volume surge

Detailed Disclosure

4 totalPositive 1Neutral 3Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-08-31
Positive[기재정정]최대주주변경을수반하는주식담보제공계약체결2026-08-27
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-08-18
Neutral반기보고서 (2026.06)2026-08-14